RxDoctor Payments Data

William Bartley, MD

Internal Medicine · Alton, ILNPI 1134112097

Payments from drug & device makers

$2,660in general payments, 2019–2025

Across 77 payments — averaging $34.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$847
  • Lilly USA, LLC$439
  • E.r. Squibb & Sons, L.L.C.$266
  • Abbott$186
  • Novo Nordisk$169
  • Astellas Pharma US Inc$159
  • plus $594 from 18 others

What the payments were for

  • Speaking & faculty fees$201%
  • Food & beverage$2,50294%
  • Education$1385%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,660 in reported general payments places this provider in the 85th percentile of 5,182 internal medicine providers in Illinois.

See all internal medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$79,638
Medicare patients
215
Services billed
904

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin181$145,828
EliquisApixaban70$62,303
OzempicSemaglutide33$40,209
TrulicityDulaglutide29$38,845
MounjaroTirzepatide27$37,424
FarxigaDapagliflozin Propanediol40$35,578
Tresiba Flextouch U-200Insulin Degludec40$33,933
Trelegy ElliptaFluticasone/Umeclidin/Vilanter43$31,762
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog51$26,559
Tresiba Flextouch U-100Insulin Degludec26$19,077
LinzessLinaclotide12$14,206
TradjentaLinagliptin17$12,781
GemtesaVibegron15$12,734
Lantus SolostarInsulin Glargine,hum.Rec.Anlog59$8,918
Breo ElliptaFluticasone/Vilanterol22$8,439

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$439$76,26956 claims
PfizerEliquis$30$62,30370 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$847$50,87266 claims
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta$71$43,19176 claims
Novo NordiskOzempic$169$40,20933 claims
AbbVieLinzess, Synthroid$35$17,03156 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 5,182 internal medicine providers in Illinois.

Other internal medicine in Alton

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →